Drug Search Results
More Filters [+]

Etonogestrel

Alternative Names: etonogestrel, implanon, nexplanon, eluryng, nuvaring, haloette, veraring
Latest Update: 2024-10-31
Latest Update Note: News Article

Product Description

Etonogestrel implant is used in women to prevent pregnancy. It is a form of birth control that contains a hormone in a flexible plastic rod about the size of a matchstick. It is effective for 3 years when inserted just beneath the skin of your upper arm. This medicine stops the release of an egg from your ovary. The mucus in your cervix thickens and may prevent sperm from reaching the egg. (Sourced from: https://www.mayoclinic.org/drugs-supplements/etonogestrel-intradermal-route/side-effects/drg-20069037?p=1)

Mechanisms of Action: ER Agonist,PR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Vaginal,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Hungary | Iceland | India | Indonesia | Ireland | Italy | Jordan | Korea | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Organon
Company Location: JERSEY CITY NJ 07302
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Etonogestrel

Countries in Clinic: Canada, India, Puerto Rico, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Contraception

Phase 2: Pregnancy Outcomes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MK-8415-060

P3

Active, not recruiting

Contraception

2024-12-28

EVE-P6-604

P1

Completed

Contraception

2023-12-11

NCT04291001

P1

Completed

Contraception

2022-10-10

CVR-WH-201

P2

Completed

Pregnancy Outcomes

2022-07-04

24%

CVR-WH-201

P2

Completed

Pregnancy Outcomes

2022-07-04

24%

Recent News Events